These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17895169)

  • 41. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
    Smith CJ; Hulme S; Vail A; Heal C; Parry-Jones AR; Scarth S; Hopkins K; Hoadley M; Allan SM; Rothwell NJ; Hopkins SJ; Tyrrell PJ
    Stroke; 2018 May; 49(5):1210-1216. PubMed ID: 29567761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
    Elkins J; Veltkamp R; Montaner J; Johnston SC; Singhal AB; Becker K; Lansberg MG; Tang W; Chang I; Muralidharan K; Gheuens S; Mehta L; Elkind MSV
    Lancet Neurol; 2017 Mar; 16(3):217-226. PubMed ID: 28229893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II).
    Adams HP; Effron MB; Torner J; Dávalos A; Frayne J; Teal P; Leclerc J; Oemar B; Padgett L; Barnathan ES; Hacke W;
    Stroke; 2008 Jan; 39(1):87-99. PubMed ID: 18032739
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group.
    Diener HC; Hacke W; Hennerici M; Rådberg J; Hantson L; De Keyser J
    Stroke; 1996 Jan; 27(1):76-81. PubMed ID: 8553408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
    Lang W; Stadler CH; Poljakovic Z; Fleet D;
    Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.
    LaMonte MP; Nash ML; Wang DZ; Woolfenden AR; Schultz J; Hursting MJ; Brown PM;
    Stroke; 2004 Jul; 35(7):1677-82. PubMed ID: 15155959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT).
    Teal P; Davis S; Hacke W; Kaste M; Lyden PD; ; Fierus M;
    Stroke; 2009 Nov; 40(11):3518-25. PubMed ID: 19745176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reassessment of defibrase in treatment of acute cerebral infarction: a multicenter, randomized, double-blind, placebo-controlled trial.
    Cooperative Group for Reassessment of Defibrase
    Chin Med Sci J; 2005 Sep; 20(3):151-8. PubMed ID: 16261883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind, placebo-controlled, randomized, multicenter study to investigate CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES Study).
    Venketasubramanian N; Chen CL; Gan RN; Chan BP; Chang HM; Tan SB; Picard D; Navarro JC; Baroque AC; Poungvarin N; Donnan GA; Bousser MG;
    Int J Stroke; 2009 Feb; 4(1):54-60. PubMed ID: 19236501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury.
    Merchant RE; Bullock MR; Carmack CA; Shah AK; Wilner KD; Ko G; Williams SA
    Ann N Y Acad Sci; 1999; 890():42-50. PubMed ID: 10668412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II studies of the glycine antagonist GV150526 in acute stroke : the North American experience. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators.
    Stroke; 2000 Feb; 31(2):358-65. PubMed ID: 10657406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist.
    Davis SM; Lees KR; Albers GW; Diener HC; Markabi S; Karlsson G; Norris J
    Stroke; 2000 Feb; 31(2):347-54. PubMed ID: 10657404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study.
    Rosenberg G; Bornstein N; Diener HC; Gorelick PB; Shuaib A; Lees K;
    Int J Stroke; 2011 Aug; 6(4):362-7. PubMed ID: 21645269
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial.
    Liu X; Xia J; Wang L; Song Y; Yang J; Yan Y; Ren H; Zhao G
    Eur J Neurol; 2009 May; 16(5):569-75. PubMed ID: 19236467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of Membrane-Activated Chelator Stroke Intervention randomized trial of DP-b99 in acute ischemic stroke.
    Lees KR; Bornstein N; Diener HC; Gorelick PB; Rosenberg G; Shuaib A;
    Stroke; 2013 Mar; 44(3):580-4. PubMed ID: 23391764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RECAST (Remote Ischemic Conditioning After Stroke Trial): A Pilot Randomized Placebo Controlled Phase II Trial in Acute Ischemic Stroke.
    England TJ; Hedstrom A; O'Sullivan S; Donnelly R; Barrett DA; Sarmad S; Sprigg N; Bath PM
    Stroke; 2017 May; 48(5):1412-1415. PubMed ID: 28265014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
    Furlan AJ; Eyding D; Albers GW; Al-Rawi Y; Lees KR; Rowley HA; Sachara C; Soehngen M; Warach S; Hacke W;
    Stroke; 2006 May; 37(5):1227-31. PubMed ID: 16574922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.